RecruitingNCT02819882
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Sponsor
Spanish Breast Cancer Research Group
Enrollment
1,867 participants
Start Date
Aug 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is building a registry to track and understand the treatment journeys and outcomes of patients with advanced breast cancer — specifically cancer that cannot be surgically removed or has spread to other parts of the body — from January 2016 onward.
**You may be eligible if...**
- You are 18 years or older
- You have been diagnosed with locally advanced breast cancer that cannot be surgically removed, or breast cancer that has spread to other parts of the body
- Your diagnosis or recurrence was from January 2016 onward
- Your medical records are available for data collection
- You are willing and able to sign a consent form if you are still living
**You may NOT be eligible if...**
- There are no exclusion criteria for this study
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNo intervention
Locations(40)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02819882
Related Trials
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807183 locations
Breast Cancer, Reasoning, and Activity Intervention
NCT048160061 location
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700296 locations
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
NCT05573893107 locations
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
NCT072222151 location